We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

EVR:LSEEvraz PLC Analysis

Data as of 2026-05-22 - not real-time

$346.26

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Evercore delivered a record Q1 2026 with revenue climbing to $4.55 bn and a 16.4% profit margin, while operating margins held near 24% and ROE surged above 40%. EPS jumped to $17.76 and the forward estimate of $23.01 suggests continued earnings acceleration. The company’s dividend payout remains modest at 19% of earnings, supporting a sustainable 1.03% yield. Despite a price‑to‑earnings multiple of ~19.5x that exceeds the industry average of 16.7x, the DCF model flags a fair value near $1,014, implying the stock is still priced attractively relative to its cash generation and growth prospects. Technically, the share price of $346 sits above the 20‑day, 50‑day and 200‑day SMAs, indicating short‑term bullish momentum, though the MACD histogram has turned negative and volume is trending down, tempering the upside.
Risk factors include a 30‑day volatility of roughly 33% and a beta above 1.8, pointing to heightened market sensitivity. The decreasing trading volume and a sizable max drawdown of ~30% suggest liquidity and downside risk, while the capital‑markets sector carries moderate regulatory exposure. Overall, the fundamentals are strong, the dividend is sustainable, but valuation appears only marginally justified, leading to a cautious yet positive outlook.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Q1 earnings beat expectations
  • Price above key moving averages
  • Support level near $311.6 providing downside cushion

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • PE multiple above industry peers
  • Negative MACD histogram indicating potential pullback
  • Sustained dividend with low payout ratio

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • High ROE and strong cash flow generation
  • DCF fair value suggests significant upside
  • Diversified global footprint reduces geographic concentration

Key Metrics & Analysis

Financial Health

Revenue Growth100.30%
Profit Margin16.40%
P/E Ratio19.5
ROE42.17%
ROA21.35%
Debt/Equity52.59
P/B Ratio7.5
Op. Cash Flow$1.6B
Industry P/E16.7

Technical Analysis

TrendNeutral
RSI57.9
Support$311.60
Resistance$351.65
MA 20$333.62
MA 50$319.79
MA 200$326.57
MACDBearish
VolumeDecreasing
Fear & Greed Index90.93

Valuation

Fair Value$1,014.23
Target Price$374.60
Upside/Downside8.18%
GradeFair
TypeBlend
Dividend Yield1.03%

Risk Assessment

Beta1.84
Volatility32.94%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.